Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854458 · ClinicalTrials.gov registry record · NA
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
A NA study of Ischemic Heart Disease (IHD) and Cardiac Magnetic Resonance Imaging, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 7
- Study locations
NCT06854458: Recruiting NA study of Ischemic Heart Disease (IHD) and Cardiac Magnetic Resonance Imaging, sponsored by Brigham and Women's Hospital.
NCT06854458 is a NA study of Ischemic Heart Disease (IHD) and Cardiac Magnetic Resonance Imaging that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06854458, a NA study of Ischemic Heart Disease (IHD) and Cardiac Magnetic Resonance Imaging, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.
Primary Outcome
Composite MACE includes cardiovascular death, non-fatal acute myocardial infarction, stroke, resuscitated cardiac arrest, unnecessary invasive coronary angiography, and any cardiac hospitalization. Unnecessary invasive coronary angiography is defined as any invasive coronary angiography performed within 6 months after study enrollment, which reviews no obstructive coronary disease and no revascularization performed.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw for the laboratory assessment
- DIAGNOSTIC_TEST Quantitative Myocardial Blood Flow Evaluation
- DIAGNOSTIC_TEST Qualitative Myocardial Blood Flow Evaluation
- DRUG Gadavist
- DRUG Vasodilator
Study Locations (7)
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California San Francisco - San Francisco
North Carolina
- Atrium Health - Sanger Heart & Vascular Institute - Charlotte
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- Houston Methodist Hospital - Houston
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2029-03 |
| Phase | NA |
What NCT06854458 shows while recruiting
NCT06854458 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 3 conditions, with Ischemic Heart Disease (IHD) appearing as the primary indexed condition, and to 5 interventions - of which Blood draw for the laboratory assessment is the first listed.
NCT06854458 lists 7 locations in 6 states (Massachusetts, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06854458 about?
NCT06854458 is a clinical study titled "The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study". This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac ...
What is the current status of trial NCT06854458?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-06-27. Estimated completion is 2029-03.
What conditions does trial NCT06854458 study?
This clinical trial studies the following conditions: Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow.
What interventions are being tested in trial NCT06854458?
The interventions under investigation include: Blood draw for the laboratory assessment (DIAGNOSTIC_TEST), Quantitative Myocardial Blood Flow Evaluation (DIAGNOSTIC_TEST), Qualitative Myocardial Blood Flow Evaluation (DIAGNOSTIC_TEST), Gadavist (DRUG), Vasodilator (DRUG).
Who is sponsoring clinical trial NCT06854458?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06854458 being conducted?
This trial has 7 study locations across California, Massachusetts, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease (IHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06854458's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI